Cambridge Investment Research Advisors
RMD icon

Cambridge Investment Research Advisors’s ResMed RMD Stock Holding History

Cambridge Investment Research Advisors’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Sell
10,105
-924
-8% -$230K 0.01% 1501
2025
Q4 		$2.66M Buy
11,029
+594
+6% +$152K 0.01% 1307
2025
Q3 		$2.86M Buy
10,435
+699
+7% +$191K 0.01% 1241
2025
Q2 		$2.51M Buy
9,736
+605
+7% +$144K 0.01% 1258
2025
Q1 		$2.04M Sell
9,131
-554
-6% -$129K 0.01% 1324
2024
Q4 		$2.21M Buy
9,685
+531
+6% +$128K 0.01% 1295
2024
Q3 		$2.23M Buy
9,154
+1,302
+17% +$291K 0.01% 1269
2024
Q2 		$1.5M Buy
7,852
+871
+12% +$177K 0.01% 1487
2024
Q1 		$1.38M Sell
6,981
-7,903
-53% -$1.45M 0.01% 1508
2023
Q4 		$2.56M Buy
14,884
+9,442
+174% +$1.45M 0.01% 1045
2023
Q3 		$805K Buy
5,442
+1,863
+52% +$337K ﹤0.01% 1714
2023
Q2 		$782K Buy
3,579
+374
+12% +$83.4K ﹤0.01% 1788
2023
Q1 		$702K Buy
3,205
+111
+4% +$24.1K ﹤0.01% 1826
2022
Q4 		$644K Sell
3,094
-95
-3% -$20.9K ﹤0.01% 1830
2022
Q3 		$696K Sell
3,189
-232
-7% -$52.8K ﹤0.01% 1718
2022
Q2 		$717K Buy
3,421
+371
+12% +$79K ﹤0.01% 1699
2022
Q1 		$740K Buy
3,050
+414
+16% +$100K ﹤0.01% 1808
2021
Q4 		$687K Buy
2,636
+162
+7% +$42K ﹤0.01% 1854
2021
Q3 		$652K Buy
2,474
+695
+39% +$190K ﹤0.01% 1840
2021
Q2 		$439K Sell
1,779
-85
-5% -$17.9K ﹤0.01% 2155
2021
Q1 		$362K Sell
1,864
-267
-13% -$53.5K ﹤0.01% 2151
2020
Q4 		$453K Sell
2,131
-324
-13% -$64.6K ﹤0.01% 1835
2020
Q3 		$421K Sell
2,455
-1,378
-36% -$254K ﹤0.01% 1716
2020
Q2 		$736K Buy
3,833
+232
+6% +$38K 0.01% 1313
2020
Q1 		$530K Buy
3,601
+891
+33% +$142K 0.01% 1330
2019
Q4 		$420K Sell
2,710
-44
-2% -$6.34K ﹤0.01% 1690
2019
Q3 		$372K Buy
2,754
+187
+7% +$24.5K ﹤0.01% 1688
2019
Q2 		$313K Sell
2,567
-12,025
-82% -$1.33M ﹤0.01% 1721
2019
Q1 		$1.52M Sell
14,592
-128
-0.9% -$13.2K 0.01% 833
2018
Q4 		$1.68M Buy
14,720
+1,142
+8% +$122K 0.02% 700
2018
Q3 		$1.57M Buy
13,578
+930
+7% +$102K 0.02% 786
2018
Q2 		$1.31M Buy
+12,648
New +$1.28M 0.01% 837
2017
Q2 		– Sell
-2,944
Closed -$212K – 1978
2017
Q1 		$212K Buy
+2,944
New +$203K ﹤0.01% 1580
2015
Q2 		– Sell
-9,470
Closed -$680K – 1485
2015
Q1 		$680K Sell
9,470
-177
-2% -$11.5K 0.02% 654
2014
Q4 		$541K Buy
+9,647
New +$504K 0.02% 739

Other funds holding RMD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Cambridge Investment Research Advisors's RMD Position: Q1 2026 in Review

Cambridge Investment Research Advisors reduced its ResMed (RMD) stake by 8.4% in Q1 2026, selling an estimated $230K and leaving 10,105 shares worth $2.27M. The position accounts for 0.01% of the portfolio, ranked #1501.

Cambridge Investment Research Advisors first reported a position in RMD in Q4 2014 and has held it in 35 quarters since. The position peaked at $2.86M in Q3 2025. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

  • Cambridge Investment Research Advisors held 10,105 shares of ResMed worth $2.27M as of Q1 2026.
  • Cambridge Investment Research Advisors sold 924 ResMed shares in Q1 2026, an estimated $230K.
  • ResMed made up 0.01% of Cambridge Investment Research Advisors's portfolio in Q1 2026, its #1501 holding.
  • Cambridge Investment Research Advisors first reported a position in ResMed in Q4 2014 and has held it in 35 quarters since.
  • Cambridge Investment Research Advisors's ResMed position peaked at $2.86M in Q3 2025.
  • 938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on Cambridge Investment Research Advisors's 13F filing for Q1 2026, filed 30 Apr 2026.